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Direct current electrical cardioversion (DC-ECV) is the preferred treatment for the termination of paroxysmal atrial ﬁbrillation
(AF) that occurs during radiofrequency ablation (RFA) of supraventricular tachycardias (SVT). Intravenous Ibutilide may be an
alternative option in this setting. Thirty-four out of 386 patients who underwent SVT-RFA presented paroxysmal AF during the
procedure and were randomized into receiving ibutilide or DC-ECV. Ibutilide infusion successfully cardioverted 16 out of 17
patients (94%) within 17.37±7.87 min. DC-ECV was successful in all patients (100%) within 17.29±3.04 min. Eﬃcacy and total
time to cardioversion did not diﬀer between the study groups. No adverse events were observed. RFA was successfully performed
in 16 patients (94%) in the ibutilide arm and in all patients (100%) in the DC-ECV arm, p = NS. In conclusion, ibutilide is a safe
and eﬀective alternative treatment for restoring sinus rhythm in cases of paroxysmal AF complicating SVT-RFA.
1.Introduction
Radiofrequency catheter ablation (RFA) has been established
as an eﬀective treatment for supraventricular tachycar-
dias (SVT) [1, 2]. Paroxysmal atrial ﬁbrillation (AF) may
occasionally complicate SVT-RFA, resulting in repetitive
electrical cardioversions and undesirable procedure delays.
Ibutilide is a newer class III antiarrhythmic agent for the
cardioversion of AF and atrial ﬂutter [3–5]. Unlike other
class III agents which block the rapid component of the
delayed rectiﬁer outward potassium channels (Ikr), ibutilide
activates the slow inward currents (mainly sodium current).
Theseantiarrhythmicactionsresultinprolongationofaction
potential duration and refractoriness of normal myocardial
tissue [3–5] and, therefore, the termination of re-entry
arrhythmias such as atrial ﬁbrillation and atrial ﬂutter.
However, ibutilide may also result in prolongation of the
QT interval and increased risk for polymorphic ventricular
tachycardias [4, 6, 7]. The safety of ibutilide in terminating
paroxysmal atrial ﬁbrillation has been previously shown in
various populations [8]. The eﬀect of ibutilide in the setting
of electrophysiological testing and ablation procedures has
not been adequately studied. The aim of this study was to
assess the safety and eﬃcacy of ibutilide versus direct current
electrical cardioversion (DC-ECV) for the termination of
paroxysmalAFcomplicatingRFAforsupraventriculartachy-
cardias.
2. Methods
2.1. Patient Population. Over a period of 47 months, 386
patients undergoing RFA for SVT in our laboratory were
screened for eligibility in the study. Eligible was considered
every patient who presented new onset AF during the RFA
procedure that was not self-terminating after 15 minutes.
Additional inclusion criteria were sinus rhythm at the begin-
ning of the procedure, absence of structural heart disease,
ventricular rate of at least 60 beats/min, QTc ≤ 440msec on
12-lead electrocardiogram, heamodynamic stability (systolic
blood pressure >90mmHg), normal hepatic and renal
function,nohistoryoftorsadesdepointes,andnosymptoms
or signs of congestive heart failure or unstable angina. New2 Cardiology Research and Practice
Table 1: Population characteristics.
Ibutilide N = 17 DC-ECV N = 17 P value
Gender (male/female) 8/9 10/7 NS
Age (years) 46 ± 23 47 ± 22 NS
QRS duration (msec) 79 ± 77 7 ± 7N S
QTc duration (msec) 383 ± 34 381 ± 25 NS
Heart rate (beats per minute) 74 ± 12 74 ± 9N S
Clinical tachycardia
AFL (isthmus-dependent) 6 6 NS
AVNRT 7 6 NS
AVRT (concealed accessory pathway) 2 3 NS
AT 2 2 NS
DC-ECV: direct current external cardioversion; AFL: atrial ﬂutter; AVNRT: atrioventricular nodal re-entry tachycardia; AVRT: atrioventricular re-entry
tachycardia; AT: atrial tachycardia; NS: nonsigniﬁcant.
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(14%) either spontaneously during catheter manipulation or
during the stimulation protocol and was self-terminating in
32 patients within 15 minutes from onset. The remaining 34
patients, in whom AF persisted for more than 15 minutes,
met the previous additional inclusion criteria and were
enrolled in the study and randomized into two groups.
Group A consisted of 17 patients who received ibutilide and
group B of 17 patients who received DC-ECV. The study
protocol complied with the Declaration of Helsinki and was
approved by the Ethics Committee of our Institution.
2.2. Drug Infusion. All patients were over 18 years old and
weighted ≥60Kg. One mg of ibutilide was infused undi-
luted intravenously over 10 minutes under continuous
electrocardiographic and blood pressure monitoring until
cardioversion occurred. If cardioversion was not achieved 10
minutes after the end of the ﬁrst infusion, a second dose of
1mg was administered, until sinus rhythm was restored or
the maximum dose of 2mg was reached.
2.3. DC Cardioversion. Sedation was performed by an anes-
thetist using intravenous administration of propofol. Initial
dose of propofol was 0.5–1mg/Kg with further uptitration
until adequate sedation was achieved, under continuous
electrocardiographic, oxygen saturation, and blood pressure
monitoring. Adequate sedation was determined by loss of
response to verbal stimulus or tactile stimulus. Sedation
time was recorded as the time from ﬁrst injection to the
time of adequate sedation. DC cardioversion was performed
using a monophasic deﬁbrillator giving a ﬁrst shock of 200
joules followed by a second shock of 360 joules in case of
noncardioversion.
2.4. RFA Procedure. All antiarrhythmic drugs were disconti-
nued for >5 half-lives before the procedure except for
amiodarone, which was discontinued 2 weeks before the
procedure. In cases of typical atrial ﬂutter, the cava tricuspid
isthmus was targeted using standard protocol as previously
described [9]. Interruption was validated with diﬀerential
pacing. For atrial tachycardia (AT) cases the site of earliest
activation during tachycardia was targeted. Slow pathway
ablationusinganatomiccriteriawasusedforatrioventricular
nodal reentrant tachycardia (AVNRT), and the site of
the shortest ventriculoatrial interval during atrioventricu-
lar reentrant tachycardia (AVRT) was primarily used for
concealed pathways. A 12-lead surface electrocardiogram
and bipolar intracardiac electrograms were simultaneously
recorded from the high right atrium, coronary sinus, His
bundle region, right ventricular apex, and left atrium
(where appropriate). Electrical stimulation was performed
with both atrial and ventricular overdrive and programmed
extrastimuluspacing. Successoftheablationwasvalidatedas
noninducibility of tachycardia.
2.5.StatisticalAnalysis. Continuousvariableswereexpressed
as mean value and standard deviation (mean ± SD), and
categorical variables were expressed as absolute numbers and
percentages. Shapiro-Wilk test was used to check for normal
distributionofdata.Comparisonsbetweengroupsweredone
with independent student’s t-test or Mann-Whitney test
fornonnormally distributed variables. Similarly, comparison
of mean values at baseline and after cardioversion was
performed with paired t-test or Wilcoxon Signed Rank test
for nonnormally distributed variables. Chi-square was used
for exploring diﬀerences between categorical variables. All
analyseswereperformedusingSPSSversus16.0forWindows
(Chicago, IL, USA). A P-value <. 05 was considered
statistically signiﬁcant.
3. Results
Patient characteristics and time intervals for cardioversion
are presented in Tables 1 and 2, respectively. Ibutilide infu-
sion (mean dose 1.35 ± 0.49mg) cardioverted successfully
16 out of 17 patients (94%) within 17.37 ± 7.87min.
This time included time for preparation and ﬁrst infusion
of ibutilide (9.75 ± 0.45min) and time from the end of
ﬁrst infusion until cardioversion (5.31 ± 3.38min), plus
additional time (total waiting period of 10 minutes between
infusions) required for a second dose administration inCardiology Research and Practice 3
Table 2: Time intervals (in minutes) for each step of ibutilide or DC-ECV cardioversion.
Group A: ibutilide Group B: DC-ECV
Patient
number
1st
infusion
N = 17
Time to
CV
N = 17
2nd
infusion
N = 4
Time to
CV N = 3
Total time
N = 16
Patient
number
Call
N = 17
Preparation/
sedation
N = 17
Shock/
recovery
N = 17
2nd shock
N = 2
Total
time
N = 17
Pt #1 9 4 0 0 13 Pt #1 2 7 5 5 19
Pt #2 10 6 0 0 16 Pt #2 3 8 6 0 17
Pt #3 9 3 0 0 12 Pt #3 3 8 5 0 16
Pt #4 10 3 0 0 13 Pt #4 2 9 5 0 16
Pt #5 10 6 0 0 16 Pt #5 2 9 4 0 15
Pt #6 9 2 0 0 11 Pt #6 1 8 5 0 14
Pt #7 10 1 0 0 11 Pt #7 1 8 7 0 16
Pt #8 10 9 0 0 19 Pt #8 3 10 8 0 21
Pt #9 10 3 0 0 13 Pt #9 2 8 4 0 14
Pt #10 10 10 0 0 20 Pt #10 4 9 6 0 19
Pt #11 10 3 0 0 13 Pt #11 2 12 12 5 26
Pt #12 9 3 0 0 12 Pt #12 2 9 5 0 16
Pt #13 10 2 0 0 12 Pt #13 3 9 4 0 16
Pt #14 10 10 10 3 33 Pt #14 3 9 7 0 19
Pt #15 10 10 10 2 32 Pt #15 3 7 4 0 14
Pt #16 10 10 10 — — Pt #16 3 8 6 0 17
Pt #17 10 10 10 2 32 Pt #17 4 8 7 0 19
Mean
±SD∗
9.75 ±
0.45
5.31 ±
3.38
10.00 ±
0.0
2.33 ±
0.58
17.37 ±
7.87 Mean±SD 2.53 ±
0.87 8.59 ± 1.18 5.88 ± 2.00 5.00 ±
0.00
17.29 ±
3.04
∗Group A (ibutilide) patient no. 16 is excluded from the calculation of mean time intervals because of failure to restore sinus rhythm. Total mean time did
not diﬀer signiﬁcantly between groups (P = .118).
DC-ECV: Direct current electrical cardioversion; CV: cardioversion.
3 patients, until sinus rhythm restoration (additional time
to cardioversion 2.33 ± 0.58min). One patient, in whom
sinus rhythm was not restored despite the maximum dose
of ibutilide, underwent successful DC-ECV. DC-ECV (200J
in 15/17 patients whereas 2/17 patients received a second
shock of 360J) was successful in all patients (100%) within
17.29 ± 3.04min. This time included time required for the
call of the anesthetist (2.53 ± 0.87min), patient preparation
and sedation (8.59 ± 1.18min), DC shock, and recovery
(5.88 ± 2.00min), plus 5 minutes for an additional shock
in 2 patients. There were no signiﬁcant diﬀerences in terms
of eﬃcacy and total time to cardioversion between the two
study groups (P>. 05).
No adverse events were observed. Ibutilide infusion was
associated with a small increase in QT duration (from 383 ±
34 to 406 ± 36, P<. 001) but no patient presented torsades
de pointes. AF relapsed in one of group B patients within
10min of initial cardioversion, and an additional 360J shock
was applied successfully. No relapse was observed in Group
A patients.
The RFA procedure was completed successfully in all
but one patient (this patient had atrial tachycardia which
was noninducible postibutilide infusion). RFA for atrial
ﬂutter (12 out of 34 patients) was performed using anatomic
criteria during coronary sinus pacing and thus inducibility
was not examined. In AVRT and AVNRT cases, the clinical
tachycardias were inducible, although ibutilide slightly pro-
longed the atrioventricular nodal eﬀective refractory period
(AVNERP)by15 ±6ms.In2patientswithatrialtachycardia,
a prolongation of the atrial eﬀective refractory period by
46ms and 30ms was observed after ibutilide infusion, and
atrial tachycardia was not inducible in the ﬁrst patient.
4. Discussion
In this study, we showed that ibutilide and DC-ECV are
equally eﬀective and safe methods for the cardioversion of
paroxysmal AF that complicates the RFA of various types of
supraventricular tachycardias.
Paroxysmal AF during RFA procedure that requires car-
dioversion may result in undesirable delays of the procedure.
DC-ECV is an eﬃcient and safe method for the restoration
of sinus rhythm in patients with paroxysmal AF [10, 11],
but it requires sedation, and the immediate presence of the
anesthetist is not always feasible. In our department, we
observed a rather quick response of the anesthetist that kept
the total time for DC cardioversion low. Time can also be
saved if the DC-ECV is performed without the presence of
an anesthetist by cardiologists familiar with anesthetic drugs
[12]. DC cardioversion during RFA causes further delays
because sometimes interference with the sterile ﬁeld cannot
be avoided. Moreover, DC shocks may cause displacement of4 Cardiology Research and Practice
the electrophysiology catheters, resulting in further delays of
the ablation procedure.
Glatteretal.[13]demonstratedthatintravenousibutilide
was very eﬀective and safe in patients with pre-excited
AF including children and concluded that ibutilide could
be considered as a suitable alternative to intravenous pro-
cainamide in patients with pre-excited AF. Varriale et al.
[14] showed that 1mg of ibutilide successfully terminated
AF in an 81-year-old woman with Wolf-Parkinson-White
syndrome. Sorbera and Cohen [15] gave ibutilide during
electrophysiological study to 3 patients with AF and atri-
oventricular nodal re-entry tachycardia (2 with concealed
pathways) to successfully terminate AF.
In our study, ibutilide infusion was associated with 94%
rate of cardioversion of paroxysmal AF to sinus rhythm. The
rate of successful arrhythmia termination in our study is
higher than previously reported with ibutilide [4–7]. DC-
ECV was also highly eﬀective (100%) in restoring sinus
rhythm. Relapse was observed in one patient who was
electrically cardioverted (6% within group B). Early relapse
ofparoxysmalAFaftersuccessfulDC-ECVhasbeenreported
t oo c c u ri nu pt o3 0 %o fp a t i e n t s[ 16, 17]. Our high success
and low relapse rates can be explained by the fact that the
arrhythmia was treated very early (within 15–20 minutes
of onset). It is known that the shorter the duration of the
arrhythmia is, the higher the cardioversion rate is [4, 5].
Weobservednocomplicationsinbotharmsoftreatment.
Adverse events that rarely complicate DC-ECV are sedation
related(hypotension,oxygendesaturation)andshockrelated
(ventricular ﬁbrillation, sinus pause, myocardial damage).
Gallagher et al. showed that high energy shocks of >200J
lower the risk of ventricular ﬁbrillation and are not associ-
atedwithotherseriouscomplications[18].Ibutilideinfusion
is associated with an incidence of sustained polymorphic
ventricular tachycardias which in previous studies varied
from 1.7% to 8.3% [3–6, 19]. We did not observe any
adverse eﬀects of ibutilide in this study, even though a slight
prolongation of the QTc interval was noted following ibu-
tilide infusion. Our study population consisted of apparently
healthy individuals, with structurally normal hearts and a
QTc interval <440msec at baseline. Therefore, this may
explain the absence of ventricular arrhythmias and other
complications in both arms of treatment.
Inducibility of the clinical arrhythmia during electro-
physiological study may be potentially aﬀected by any
administered drug. A small series of 12 patients with Wolf-
Parkinson-White syndrome has shown that propofol when
administered for sedation during electrophysiological study
had no eﬀect on the eﬀective refractory periods of the
atrioventricular node, right ventricle, and accessory path-
ways and did not aﬀect arrhythmia inducibility, but caused
a slight prolongation of the right atrial refractory period
[20]. Ibutilide prolongs atrial and ventricular refractory
periods and, thus, may aﬀect inducibility of the clinical
arrhythmia. In this study, 12 out of 34 patients were
treated for isthmus-dependent atrial ﬂutter and arrhythmia
inducibility was not examined. AVNRT and AVRT were
inducible in all 18 patients in both groups. Only in 1 patient
with atrial tachycardia who received ibutilide, the clinical
arrhythmia was not inducible. Ibutilide may have altered
the electrophysiologic properties of the atrium and may
have caused noninducibility of the arrhythmia. However, the
design of this study and the number of diﬀerent types of SVT
studied do not allow robust conclusions regarding the eﬀect
of ibutilide on arrhythmia inducibility.
There are several limitations in our study. None of the
included patients had abnormal heart function; thus, our
ﬁndings may not apply to patients with structural heart dis-
ease who present paroxysmal AF during SVT-RFA. Another
limitation is the small number of patients included. The
majority of our patients were treated for atrial ﬂutter, and ar-
rhythmia inducibility was not examined. Due to the under-
representation of other types of SVT, we cannot extrapolate
the observed neutral eﬀect of ibutilide on tachycardia indu-
ction to all SVT categories, especially those involving acces-
sory pathways.
In conclusion, ibutilide may be an eﬀective and safe
alternative to DC cardioversion for the termination of parox-
ysmal AF complicating electrophysiological testing and radi-
ofrequency ablation of supraventricular tachycardias in
patientswithoutstructuralheartdiseaseandnormalbaseline
QTc duration.
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